Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 16.75
(2.82%)
CNY 16.75
(2.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 121.24 Million CNY | 16.11% |
| 2022 | 104.42 Million CNY | 52.46% |
| 2021 | 68.49 Million CNY | -40.17% |
| 2020 | 114.48 Million CNY | -31.99% |
| 2019 | 168.32 Million CNY | 53.95% |
| 2018 | 109.33 Million CNY | 96.15% |
| 2017 | 55.74 Million CNY | -16.49% |
| 2016 | 66.74 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 8.43 Million CNY | -64.92% |
| 2024 Q1 | 24.03 Million CNY | -32.64% |
| 2024 Q3 | 12.69 Million CNY | 50.54% |
| 2023 Q4 | 35.68 Million CNY | 15.3% |
| 2023 FY | 121.24 Million CNY | 16.11% |
| 2023 Q3 | 30.95 Million CNY | -1.4% |
| 2023 Q2 | 31.39 Million CNY | 35.19% |
| 2023 Q1 | 23.22 Million CNY | -46.44% |
| 2022 FY | 104.42 Million CNY | 52.46% |
| 2022 Q3 | 19.09 Million CNY | -2.16% |
| 2022 Q2 | 19.51 Million CNY | -13.12% |
| 2022 Q1 | 22.46 Million CNY | 48.36% |
| 2022 Q4 | 43.35 Million CNY | 127.07% |
| 2021 Q2 | 33.57 Million CNY | 36.83% |
| 2021 Q1 | 24.54 Million CNY | 261.67% |
| 2021 FY | 68.49 Million CNY | -40.17% |
| 2021 Q4 | 15.13 Million CNY | 417.71% |
| 2021 Q3 | -4.76 Million CNY | -114.19% |
| 2020 FY | 114.48 Million CNY | -31.99% |
| 2020 Q4 | 6.78 Million CNY | -68.63% |
| 2020 Q3 | 21.62 Million CNY | -72.57% |
| 2020 Q2 | 78.84 Million CNY | 991.59% |
| 2020 Q1 | 7.22 Million CNY | -81.12% |
| 2019 Q4 | 38.26 Million CNY | -14.89% |
| 2019 Q3 | 44.96 Million CNY | 0.0% |
| 2019 FY | 168.32 Million CNY | 53.95% |
| 2018 FY | 109.33 Million CNY | 96.15% |
| 2017 FY | 55.74 Million CNY | -16.49% |
| 2016 FY | 66.74 Million CNY | 0.0% |